STOCK TITAN

[SCHEDULE 13G/A] Oric Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Viking Global and affiliated entities report a passive 9.99% position in Oric Pharmaceuticals (ORIC). The Schedule 13G/A shows Viking Global Investors LP and related funds and entities collectively beneficially own 8,729,345 shares of Oric common stock on a fully reported basis, equal to 9.99% of 85,224,191 shares outstanding (May 29, 2025 basis). Holdings arise from directly owned common stock plus pre-funded warrants exercisable for additional shares, but exercise is limited by a contractual "Blocker" that caps beneficial ownership at 9.99% (adjustable up to 19.99% with notice). Ownership is held through VGOP and VGOD (detailed share and warrant counts provided), VGI provides managerial services and has shared voting/dispositive authority, and three named executives are disclosed as having shared authority. The filing certifies the stake is not intended to influence control.

Viking Global e soggetti collegati comunicano una posizione passiva del 9,99% in Oric Pharmaceuticals (ORIC). Il Schedule 13G/A indica che Viking Global Investors LP e fondi e soggetti correlati detengono collettivamente 8.729.345 azioni ordinarie di Oric su base totalmente dichiarata, pari al 9,99% delle 85.224.191 azioni in circolazione (rilevazione al 29 maggio 2025). Le partecipazioni comprendono azioni ordinarie detenute direttamente e warrant pre-finanziati esercitabili per azioni aggiuntive, ma l'esercizio è limitato da un vincolo contrattuale ("Blocker") che limita la partecipazione beneficiaria al 9,99% — modificabile fino al 19,99% previo avviso. La proprietà è detenuta tramite VGOP e VGOD (conti dettagliati di azioni e warrant forniti); VGI fornisce servizi di gestione e condivide autorità di voto/dispositiva, e tre dirigenti nominati sono indicati come titolari di autorità condivisa. La comunicazione certifica che la partecipazione non è finalizzata a influenzare il controllo.

Viking Global y entidades afiliadas informan una posición pasiva del 9,99% en Oric Pharmaceuticals (ORIC). El Schedule 13G/A muestra que Viking Global Investors LP y fondos y entidades relacionadas poseen colectivamente 8.729.345 acciones comunes de Oric en base totalmente declarada, equivalentes al 9,99% de 85.224.191 acciones en circulación (a fecha 29 de mayo de 2025). Las participaciones proceden de acciones comunes de propiedad directa más warrants prefondados ejercitables por acciones adicionales, pero el ejercicio está limitado por un acuerdo contractual ("Blocker") que fija la propiedad beneficiaria en 9,99% — ajustable hasta 19,99% con notificación. La tenencia se mantiene a través de VGOP y VGOD (se proporcionan recuentos detallados de acciones y warrants); VGI presta servicios administrativos y comparte autoridad de voto/disposición, y tres ejecutivos nombrados figuran con autoridad compartida. La presentación certifica que la participación no pretende influir en el control.

Viking Global 및 계열사는 Oric Pharmaceuticals(ORIC)에 대한 9.99%의 수동적 지분을 보고했습니다. Schedule 13G/A에 따르면 Viking Global Investors LP와 관련 펀드 및 기관들은 총 8,729,345주의 Oric 보통주를 집계 기준으로 보유하고 있으며, 이는 발행주식 총 85,224,191주의 9.99%에 해당합니다(2025년 5월 29일 기준). 보유는 직접 보유한 보통주와 추가 주식으로 전환 가능한 선(先)자금 납입 워런트에서 발생하지만, 계약상 '블로커(Blocker)'로 인해 실질적 보유가 9.99%로 제한됩니다(통지로 최대 19.99%까지 조정 가능). 소유는 VGOP 및 VGOD를 통해 보유되고(주식 및 워런트 수는 상세 기재됨), VGI는 관리 서비스를 제공하며 의결권/처분권을 공동 보유하고 세 명의 지정 임원이 공동 권한을 보유한 것으로 공개되었습니다. 제출서류는 이 지분이 경영권 영향을 목적으로 하지 않음을 인증합니다.

Viking Global et des entités affiliées déclarent une position passive de 9,99 % dans Oric Pharmaceuticals (ORIC). Le Schedule 13G/A indique que Viking Global Investors LP et des fonds et entités liés détiennent collectivement 8 729 345 actions ordinaires d'Oric sur une base entièrement déclarée, soit 9,99 % des 85 224 191 actions en circulation (au 29 mai 2025). Les détentions proviennent d'actions ordinaires détenues directement et de warrants préfinancés exerçables pour des actions supplémentaires, mais l'exercice est limité par une clause contractuelle (« Blocker ») plafonnant la propriété bénéficiaire à 9,99 % — ajustable jusqu'à 19,99 % sur notification. La détention s'effectue via VGOP et VGOD (comptages détaillés d'actions et de warrants fournis) ; VGI fournit des services de gestion et partage l'autorité de vote/dispositive, et trois dirigeants nommés sont déclarés comme détenant une autorité partagée. Le dépôt certifie que la participation n'a pas pour but d'influencer le contrôle.

Viking Global und verbundene Gesellschaften melden eine passive Beteiligung von 9,99% an Oric Pharmaceuticals (ORIC). Das Schedule 13G/A weist aus, dass Viking Global Investors LP sowie verbundene Fonds und Einheiten zusammen 8.729.345 Stammaktien von Oric auf vollständig ausgewiesener Basis halten, was 9,99% von 85.224.191 ausstehenden Aktien entspricht (Stichtag 29. Mai 2025). Die Bestände stammen aus direkt gehaltenen Stammaktien plus vorfinanzierten Warrants, die in zusätzliche Aktien wandelbar sind; die Ausübung ist jedoch durch eine vertragliche "Blocker"-Regel begrenzt, die das wirtschaftliche Eigentum auf 9,99% deckelt (mit Mitteilung auf bis zu 19,99% anpassbar). Das Eigentum wird über VGOP und VGOD gehalten (detaillierte Stück- und Warrantzahlen angegeben); VGI erbringt Managementdienstleistungen und teilt sich Stimm- und Verfügungsgewalt, und drei benannte Führungskräfte werden mit geteilter Befugnis angegeben. Die Meldung bestätigt, dass die Beteiligung nicht darauf abzielt, die Kontrolle zu beeinflussen.

Positive
  • Transparent disclosure of a sizable economic stake (8,729,345 shares, 9.99%)
  • Clear description of share vs. warrant holdings and application of the contractual Blocker
  • Filing includes Item 10 certification confirming passive intent (not to influence control)
Negative
  • None.

Insights

TL;DR: Viking Global discloses a sizeable near-10% passive stake in ORIC via common stock and warrants, constrained by a 9.99% blocker.

The position of 8,729,345 shares (9.99%) is economically meaningful for a company with ~85.2 million shares outstanding and could be a significant shareholder block without signaling an active control intent—the filing is on Schedule 13G/A and includes an Item 10 certification that the holdings are not for control purposes. The presence of warrants increases potential upside exposure, but the Blocker currently prevents additional exercises beyond the stated cap. For modeling ownership concentration, treat this as a large passive stake with potential to increase subject to contractual limitations and notice periods.

TL;DR: Governance impact is limited now—shared voting power is disclosed, but the filing affirms a passive intent and a blocker restricts control escalation.

The filing identifies shared voting and dispositive power across multiple affiliated entities and three Executive Committee members, which is standard for fund structures. The Blocker mechanism legally constrains conversion of warrants into additional voting shares above 9.99% absent a notice and waiting period, reducing immediate governance pressure. Because the filing is a 13G/A with the Item 10 certification, this should not be treated as an activist or control-oriented disclosure, though the aggregated economic stake is large enough to be relevant in takeover or voting scenarios.

Viking Global e soggetti collegati comunicano una posizione passiva del 9,99% in Oric Pharmaceuticals (ORIC). Il Schedule 13G/A indica che Viking Global Investors LP e fondi e soggetti correlati detengono collettivamente 8.729.345 azioni ordinarie di Oric su base totalmente dichiarata, pari al 9,99% delle 85.224.191 azioni in circolazione (rilevazione al 29 maggio 2025). Le partecipazioni comprendono azioni ordinarie detenute direttamente e warrant pre-finanziati esercitabili per azioni aggiuntive, ma l'esercizio è limitato da un vincolo contrattuale ("Blocker") che limita la partecipazione beneficiaria al 9,99% — modificabile fino al 19,99% previo avviso. La proprietà è detenuta tramite VGOP e VGOD (conti dettagliati di azioni e warrant forniti); VGI fornisce servizi di gestione e condivide autorità di voto/dispositiva, e tre dirigenti nominati sono indicati come titolari di autorità condivisa. La comunicazione certifica che la partecipazione non è finalizzata a influenzare il controllo.

Viking Global y entidades afiliadas informan una posición pasiva del 9,99% en Oric Pharmaceuticals (ORIC). El Schedule 13G/A muestra que Viking Global Investors LP y fondos y entidades relacionadas poseen colectivamente 8.729.345 acciones comunes de Oric en base totalmente declarada, equivalentes al 9,99% de 85.224.191 acciones en circulación (a fecha 29 de mayo de 2025). Las participaciones proceden de acciones comunes de propiedad directa más warrants prefondados ejercitables por acciones adicionales, pero el ejercicio está limitado por un acuerdo contractual ("Blocker") que fija la propiedad beneficiaria en 9,99% — ajustable hasta 19,99% con notificación. La tenencia se mantiene a través de VGOP y VGOD (se proporcionan recuentos detallados de acciones y warrants); VGI presta servicios administrativos y comparte autoridad de voto/disposición, y tres ejecutivos nombrados figuran con autoridad compartida. La presentación certifica que la participación no pretende influir en el control.

Viking Global 및 계열사는 Oric Pharmaceuticals(ORIC)에 대한 9.99%의 수동적 지분을 보고했습니다. Schedule 13G/A에 따르면 Viking Global Investors LP와 관련 펀드 및 기관들은 총 8,729,345주의 Oric 보통주를 집계 기준으로 보유하고 있으며, 이는 발행주식 총 85,224,191주의 9.99%에 해당합니다(2025년 5월 29일 기준). 보유는 직접 보유한 보통주와 추가 주식으로 전환 가능한 선(先)자금 납입 워런트에서 발생하지만, 계약상 '블로커(Blocker)'로 인해 실질적 보유가 9.99%로 제한됩니다(통지로 최대 19.99%까지 조정 가능). 소유는 VGOP 및 VGOD를 통해 보유되고(주식 및 워런트 수는 상세 기재됨), VGI는 관리 서비스를 제공하며 의결권/처분권을 공동 보유하고 세 명의 지정 임원이 공동 권한을 보유한 것으로 공개되었습니다. 제출서류는 이 지분이 경영권 영향을 목적으로 하지 않음을 인증합니다.

Viking Global et des entités affiliées déclarent une position passive de 9,99 % dans Oric Pharmaceuticals (ORIC). Le Schedule 13G/A indique que Viking Global Investors LP et des fonds et entités liés détiennent collectivement 8 729 345 actions ordinaires d'Oric sur une base entièrement déclarée, soit 9,99 % des 85 224 191 actions en circulation (au 29 mai 2025). Les détentions proviennent d'actions ordinaires détenues directement et de warrants préfinancés exerçables pour des actions supplémentaires, mais l'exercice est limité par une clause contractuelle (« Blocker ») plafonnant la propriété bénéficiaire à 9,99 % — ajustable jusqu'à 19,99 % sur notification. La détention s'effectue via VGOP et VGOD (comptages détaillés d'actions et de warrants fournis) ; VGI fournit des services de gestion et partage l'autorité de vote/dispositive, et trois dirigeants nommés sont déclarés comme détenant une autorité partagée. Le dépôt certifie que la participation n'a pas pour but d'influencer le contrôle.

Viking Global und verbundene Gesellschaften melden eine passive Beteiligung von 9,99% an Oric Pharmaceuticals (ORIC). Das Schedule 13G/A weist aus, dass Viking Global Investors LP sowie verbundene Fonds und Einheiten zusammen 8.729.345 Stammaktien von Oric auf vollständig ausgewiesener Basis halten, was 9,99% von 85.224.191 ausstehenden Aktien entspricht (Stichtag 29. Mai 2025). Die Bestände stammen aus direkt gehaltenen Stammaktien plus vorfinanzierten Warrants, die in zusätzliche Aktien wandelbar sind; die Ausübung ist jedoch durch eine vertragliche "Blocker"-Regel begrenzt, die das wirtschaftliche Eigentum auf 9,99% deckelt (mit Mitteilung auf bis zu 19,99% anpassbar). Das Eigentum wird über VGOP und VGOD gehalten (detaillierte Stück- und Warrantzahlen angegeben); VGI erbringt Managementdienstleistungen und teilt sich Stimm- und Verfügungsgewalt, und drei benannte Führungskräfte werden mit geteilter Befugnis angegeben. Die Meldung bestätigt, dass die Beteiligung nicht darauf abzielt, die Kontrolle zu beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G




Comment for Type of Reporting Person: See Item 4


SCHEDULE 13G



VIKING GLOBAL INVESTORS LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Parent GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Portfolio GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Illiquid Investments Sub-Master LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Drawdown GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Drawdown Portfolio GP LLC
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown Portfolio GP LLC (1)(2)(3)
Date:08/14/2025
Viking Global Opportunities Drawdown (Aggregator) LP
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown (Aggregator) LP (1)(2)(3)
Date:08/14/2025
HALVORSEN OLE ANDREAS
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
Date:08/14/2025
Ott David C.
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of David C. Ott (2)
Date:08/14/2025
Shabet Rose Sharon
Signature:/s/ Scott M. Hendler
Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (3)
Date:08/14/2025

Comments accompanying signature: (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
Exhibit Information

EXHIBIT A - JOINT FILING AGREEMENT

FAQ

How many Oric Pharmaceuticals (ORIC) shares do Viking Global and affiliates report owning?

The Reporting Persons disclose beneficial ownership of 8,729,345 shares of ORIC common stock, representing 9.99% of 85,224,191 shares outstanding (May 29, 2025 basis).

Does the Schedule 13G/A include warrants in the ownership calculation for ORIC?

Yes. The filing counts directly owned common stock plus pre-funded warrants exercisable into common stock, but exercise rights are limited by a contractual Blocker that caps ownership at 9.99% unless adjusted with notice.

Which Viking entities hold the ORIC position and how are the shares allocated?

Holdings are through VGOP (4,312,800 shares plus rights to 1,293,987 shares via warrants) and VGOD (2,259,900 shares plus rights to 862,658 shares via warrants), with aggregate reporting by VGI and related GP/portfolio entities.

Does this filing indicate Viking Global seeks to influence control of Oric Pharmaceuticals?

No. Item 10 of the filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing control; the Schedule filed is a 13G/A (passive) filing.

What is the Blocker and how does it affect potential warrant exercises?

The Blocker prevents holders from exercising warrants to the extent that exercise would cause beneficial ownership to exceed 9.99% (the blocker can be adjusted up to 19.99% with notice, effective after a 61-day delay).
Oric Pharmaceuticals, Inc.

NASDAQ:ORIC

ORIC Rankings

ORIC Latest News

ORIC Latest SEC Filings

ORIC Stock Data

954.72M
76.35M
7.9%
102.15%
14.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO